Ghent University Academic Bibliography

Advanced

A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients

Viens, P, Petit, T, Yovine, A, Bougnoux, P, Deplanque, G, Cottu, P, Delva, R, Lotz, J, Van Belle, Simon UGent, Extra, J, et al. (2006) ANNALS OF ONCOLOGY. 17(3). p.429-436
abstract
Purpose: A multicentric, phase II study to evaluate the efficacy and safety of the combination paclitaxel and oxaliplatin in patients with platinum-sensitive recurrent ovarian cancer. Patients and methods: Patients received 175 mg/m(2) paclitaxel (over 3 h) followed by 130 mg/m(2) oxaliplatin (over 2 h) every 21 days for up to nine cycles without hydration or primary granulocyte colony-stimulating factor prophylaxis. Patients had to have an Eastern Cooperative Oncology Group performance status of 0-2 and to have received no more than one prior cisplatin- and/or carboplatin-containing chemotherapy regimen with a platinum-progression-free interval >= 6 months. Results: Of the 105 patients enrolled and treated, 98 were eligible. An overall response rate of 81% (79 of 98 patients) (95% confidence interval 71% to 88%) was observed according to RECIST criteria (third party reviewed), and 88% (86 of 98) when this was complemented with CA-125 response. With a median follow up of 43.6 months (range 30.2-64.2) the median progression-free survival was 10.2 months (range 0.3-21.4) and the overall survival 32.4 months. Seven hundred and eight cycles were administered (median seven per patient; range one to nine). A total of 67% of patients experienced National Cancer Institute Common Toxicity Criteria grade 3-4 neutropenia, including 8% with concomitant febrile episode, without treatment-related deaths. Ninety-three per cent of patients experienced neuropathy of grade 1 or more, including 25% with cumulative reversible peripheral neuropathy of grade 3-4. Oxaliplatin doses were reduced in 30 patients due to neurotoxicity. Conclusions: The oxaliplatin/paclitaxel combination can be administered in an outpatient setting every 3 weeks without specific measures. The high level of activity and its duration observed warrants further evaluation of this combination in pretreated platinum-sensitive advanced ovarian cancer patients.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
DNA MISMATCH REPAIR, GYNECOLOGIC-ONCOLOGY-GROUP, 2ND-LINE THERAPY, SINGLE-AGENT, CLINICAL-TRIAL, SOLID TUMORS, STAGE-III, CISPLATIN, CARBOPLATIN, CARCINOMA, ovarian cancer, oxaliplatin, paclitaxel, phase II, platinum-sensitive
journal title
ANNALS OF ONCOLOGY
Ann. Oncol.
volume
17
issue
3
pages
429 - 436
Web of Science type
Article
Web of Science id
000235770700011
JCR category
ONCOLOGY
JCR impact factor
5.179 (2006)
JCR rank
21/125 (2006)
JCR quartile
1 (2006)
ISSN
0923-7534
DOI
10.1093/annonc/mdj097
language
English
UGent publication?
yes
classification
A1
id
356871
handle
http://hdl.handle.net/1854/LU-356871
date created
2007-03-19 15:38:00
date last changed
2016-12-19 15:44:38
@article{356871,
  abstract     = {Purpose: A multicentric, phase II study to evaluate the efficacy and safety of the combination paclitaxel and oxaliplatin in patients with platinum-sensitive recurrent ovarian cancer. Patients and methods: Patients received 175 mg/m(2) paclitaxel (over 3 h) followed by 130 mg/m(2) oxaliplatin (over 2 h) every 21 days for up to nine cycles without hydration or primary granulocyte colony-stimulating factor prophylaxis. Patients had to have an Eastern Cooperative Oncology Group performance status of 0-2 and to have received no more than one prior cisplatin- and/or carboplatin-containing chemotherapy regimen with a platinum-progression-free interval {\textrangle}= 6 months. Results: Of the 105 patients enrolled and treated, 98 were eligible. An overall response rate of 81\% (79 of 98 patients) (95\% confidence interval 71\% to 88\%) was observed according to RECIST criteria (third party reviewed), and 88\% (86 of 98) when this was complemented with CA-125 response. With a median follow up of 43.6 months (range 30.2-64.2) the median progression-free survival was 10.2 months (range 0.3-21.4) and the overall survival 32.4 months. Seven hundred and eight cycles were administered (median seven per patient; range one to nine). A total of 67\% of patients experienced National Cancer Institute Common Toxicity Criteria grade 3-4 neutropenia, including 8\% with concomitant febrile episode, without treatment-related deaths. Ninety-three per cent of patients experienced neuropathy of grade 1 or more, including 25\% with cumulative reversible peripheral neuropathy of grade 3-4. Oxaliplatin doses were reduced in 30 patients due to neurotoxicity. Conclusions: The oxaliplatin/paclitaxel combination can be administered in an outpatient setting every 3 weeks without specific measures. The high level of activity and its duration observed warrants further evaluation of this combination in pretreated platinum-sensitive advanced ovarian cancer patients.},
  author       = {Viens, P and Petit, T and Yovine, A and Bougnoux, P and Deplanque, G and Cottu, P and Delva, R and Lotz, J and Van Belle, Simon and Extra, J and Cvitkovic, E},
  issn         = {0923-7534},
  journal      = {ANNALS OF ONCOLOGY},
  keyword      = {DNA MISMATCH REPAIR,GYNECOLOGIC-ONCOLOGY-GROUP,2ND-LINE THERAPY,SINGLE-AGENT,CLINICAL-TRIAL,SOLID TUMORS,STAGE-III,CISPLATIN,CARBOPLATIN,CARCINOMA,ovarian cancer,oxaliplatin,paclitaxel,phase II,platinum-sensitive},
  language     = {eng},
  number       = {3},
  pages        = {429--436},
  title        = {A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients},
  url          = {http://dx.doi.org/10.1093/annonc/mdj097},
  volume       = {17},
  year         = {2006},
}

Chicago
Viens, P, T Petit, A Yovine, P Bougnoux, G Deplanque, P Cottu, R Delva, et al. 2006. “A Phase II Study of a Paclitaxel and Oxaliplatin Combination in Platinum-sensitive Recurrent Advanced Ovarian Cancer Patients.” Annals of Oncology 17 (3): 429–436.
APA
Viens, P., Petit, T., Yovine, A., Bougnoux, P., Deplanque, G., Cottu, P., Delva, R., et al. (2006). A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. ANNALS OF ONCOLOGY, 17(3), 429–436.
Vancouver
1.
Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu P, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. ANNALS OF ONCOLOGY. 2006;17(3):429–36.
MLA
Viens, P, T Petit, A Yovine, et al. “A Phase II Study of a Paclitaxel and Oxaliplatin Combination in Platinum-sensitive Recurrent Advanced Ovarian Cancer Patients.” ANNALS OF ONCOLOGY 17.3 (2006): 429–436. Print.